CD44: Survival and metastasis in chondrosarcoma

Osteoarthritis and Cartilage

Volumn 18, Issue 6, 2010, Pages 849-856

  Heyse, T J ^a   Malcherczyk, D ^a   Moll, R ^a   Timmesfeld, N ^b   Wapelhorst, J ^a   Fuchs Winkelmann, S ^a   Paletta, J R J ^a   Schofer, M D ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b Inst Med Biometr and Epidemiol   (Germany)

Author keywords

CD44; Chondrosarcoma; Grading; Immunohistochemistry; Metastasis; Prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT; CD44V5 ANTIGEN; CD44V6 ANTIGEN; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE RESECTION; CANCER CLASSIFICATION; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHONDROSARCOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; MALE; METASTASIS; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; CHONDROSARCOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROTEIN ISOFORMS; YOUNG ADULT;

EID: 77952877280     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2010.02.007     Document Type: Article

References (49)

1. Fletcher CDM, Krishnan Unni K, Mertens F. Pathology and genetics of tumors of soft tissue and bone - chondrosarkoma, 2002.
2. Schajowicz F. Tumors and Tumor like Lesions of Bone 1994, Springer, New York.
3. Dorfman H.D., Czerniak B. Bone cancers. Cancer 1995 Jan 1, 75(1 Suppl):203-210.
4. Murphey M.D., Walker E.A., Wilson A.J., Kransdorf M.J., Temple H.T., Gannon F.H. From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation. Radiographics 2003 Sep-Oct, 23(5):1245-1278.
5. Evans H.L., Ayala A.G., Romsdahl M.M. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer 1977 Aug, 40(2):818-831.
6. Lee F.Y., Mankin H.J., Fondren G., Gebhardt M.C., Springfield D.S., Rosenberg A.E., et al. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am 1999 Mar, 81(3):326-338.
7. Picker L.J., Nakache M., Butcher E.C. Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types. J Cell Biol 1989 Aug, 109(2):927-937.
8. Screaton G.R., Bell M.V., Bell J.I., Jackson D.G. The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human, and rat. J Biol Chem 1993 Jun 15, 268(17):12235-12238.
9. Screaton G.R., Bell M.V., Jackson D.G., Cornelis F.B., Gerth U., Bell J.I. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci U S A 1992 Dec 15, 89(24):12160-12164.
10. Stamenkovic I., Aruffo A., Amiot M., Seed B. The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J 1991 Feb, 10(2):343-348.
11. Aruffo A., Stamenkovic I., Melnick M., Underhill C.B., Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990 Jun 29, 61(7):1303-1313.
12. St John T., Meyer J., Idzerda R., Gallatin W.M. Expression of CD44 confers a new adhesive phenotype on transfected cells. Cell 1990 Jan 12, 60(1):45-52.
13. Ponta H., Sherman L., Herrlich P.A. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003 Jan, 4(1):33-45.
14. Marhaba R., Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 2004 Mar, 35(3):211-231.
15. Christ O., Gunthert U., Schmidt D.S., Zoller M. Allogeneic reconstitution after nonmyeloablative conditioning: mitigation of graft-versus-host and host-versus-graft reactivity by anti-CD44v6. J Leukoc Biol 2002 Jan, 71(1):33-46.
16. Gunthert U., Hofmann M., Rudy W., Reber S., Zoller M., Haussmann I., et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991 Apr 5, 65(1):13-24.
17. Kahara N., Ozaki T., Doi T., Nishida K., Kawai A., Shibahara M., et al. CD44 expression in soft tissue sarcomas. Virchows Arch 2000 Jun, 436(6):574-578.
18. Noordzij M.A., van Steenbrugge G.J., Verkaik N.S., Schroder F.H., van der Kwast T.H. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res 1997 May, 3(5):805-815.
19. Dall P., Heider K.H., Hekele A., von Minckwitz G., Kaufmann M., Ponta H., et al. Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. Cancer Res 1994 Jul 1, 54(13):3337-3341.
20. Heider K.H., Dammrich J., Skroch-Angel P., Muller-Hermelink H.K., Vollmers H.P., Herrlich P., et al. Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 1993 Sep 15, 53(18):4197-4203.
21. Joensuu H., Klemi P.J., Toikkanen S., Jalkanen S. Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol 1993 Sep, 143(3):867-874.
22. Joensuu H., Ristamaki R., Klemi P.J., Jalkanen S. Lymphocyte homing receptor (CD44) expression is associated with poor prognosis in gastrointestinal lymphoma. Br J Cancer 1993 Aug, 68(2):428-432.
23. Kuppner M.C., Van Meir E., Gauthier T., Hamou M.F., de Tribolet N. Differential expression of the CD44 molecule in human brain tumours. Int J Cancer 1992 Feb 20, 50(4):572-577.
24. Washimi O., Ueda R., Ariyoshi Y., Suyama M., Seki T., Takahashi T., et al. Expression of CD44 variant isoforms in normal and neoplastic cells of the lung. Jpn J Cancer Res 1994 Nov, 85(11):1112-1116.
25. Washington K., Gottfried M.R., Telen M.J. Expression of the cell adhesion molecule CD44 in gastric adenocarcinomas. Hum Pathol 1994 Oct, 25(10):1043-1049.
26. Tanabe K.K., Ellis L.M., Saya H. Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet 1993 Mar 20, 341(8847):725-726.
27. Terpe H.J., Koopmann R., Imhof B.A., Gunthert U. Expression of integrins and CD44 isoforms in non-Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas. J Pathol 1994 Oct, 174(2):89-100.
28. Wielenga V.J., Heider K.H., Offerhaus G.J., Adolf G.R., van den Berg F.M., Ponta H., et al. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993 Oct 15, 53(20):4754-4756.
29. Kim H.S., Park Y.B., Oh J.H., Jeong J., Kim C.J., Lee S.H. Expression of CD44 isoforms correlates with the metastatic potential of osteosarcoma. Clin Orthop Relat Res 2002 Mar, 396:184-190.
30. Kuryu M., Ozaki T., Nishida K., Shibahara M., Kawai A., Inoue H. Expression of CD44 variants in osteosarcoma. J Cancer Res Clin Oncol 1999 Nov, 125(11):646-652.
31. Bosch P.P., Stevens J.W., Noonan K.J., Buckwalter J.A., Midura R.J. Expression of CD44 in human neoplastic and normal hyaline cartilage. Iowa Orthop J 2002, 22:47-54.
32. Endo M., Matsumura T., Yamaguchi T., Yamaguchi U., Morimoto Y., Nakatani F., et al. Cyclooxygenase-2 overexpression associated with a poor prognosis in chondrosarcomas. Hum Pathol 2006 Apr, 37(4):471-476.
33. Tibesku C.O., Szuwart T., Ocken S.A., Skwara A., Fuchs S. Increase in the expression of the transmembrane surface receptor CD44v6 on chondrocytes in animals with osteoarthritis. Arthritis Rheum 2005 Mar, 52(3):810-817.
34. Tibesku C.O., Szuwart T., Ocken S.A., Skwara A., Fuchs S. Expression of the matrix receptor CD44v5 on chondrocytes changes with osteoarthritis: an experimental investigation in the rabbit. Ann Rheum Dis 2006 Jan, 65(1):105-108.
35. Nakamura H., Kato R., Hirata A., Inoue M., Yamamoto T. Localization of CD44 (hyaluronan receptor) and hyaluronan in rat mandibular condyle. J Histochem Cytochem 2005 Jan, 53(1):113-120.
36. Ostergaard K., Salter D.M., Andersen C.B., Petersen J., Bendtzen K. CD44 expression is up-regulated in the deep zone of osteoarthritic cartilage from human femoral heads. Histopathology 1997 Nov, 31(5):451-459.
37. Albrecht C., Schlegel W., Eckl P., Jagersberger T., Sadeghi K., Berger A., et al. Alterations in CD44 isoforms and HAS expression in human articular chondrocytes during the de- and re-differentiation processes. Int J Mol Med 2009 Feb, 23(2):253-259.
38. Knudson W., Aguiar D.J., Hua Q., Knudson C.B. CD44-anchored hyaluronan-rich pericellular matrices: an ultrastructural and biochemical analysis. Exp Cell Res 1996 Nov 1, 228(2):216-228.
39. Ishida O., Tanaka Y., Morimoto I., Takigawa M., Eto S. Chondrocytes are regulated by cellular adhesion through CD44 and hyaluronic acid pathway. J Bone Miner Res 1997 Oct, 12(10):1657-1663.
40. Yoshida M., Yasuda T., Hiramitsu T., Ito H., Nakamura T. Induction of apoptosis by anti-CD44 antibody in human chondrosarcoma cell line SW1353. Biomed Res 2008 Feb, 29(1):47-52.
41. Kobayashi H., Suzuki M., Kanayama N., Nishida T., Takigawa M., Terao T. CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells. Int J Cancer 2002 Dec 1, 102(4):379-389.
42. Fiorenza F., Abudu A., Grimer R.J., Carter S.R., Tillman R.M., Ayoub K., et al. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br 2002 Jan, 84(1):93-99.
43. Kaufmann M., Heider K.H., Sinn H.P., von Minckwitz G., Ponta H., Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995 Mar 11, 345(8950):615-619.
44. Friedrichs K., Franke F., Lisboa B.W., Kugler G., Gille I., Terpe H.J., et al. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 1995 Nov 15, 55(22):5424-5433.
45. Bhatavdekar J.M., Patel D.D., Chikhlikar P.R., Trivedi T.I., Gosalia N.M., Ghosh N., et al. Overexpression of CD44: a useful independent predictor of prognosis in patients with colorectal carcinomas. Ann Surg Oncol 1998 Sep, 5(6):495-501.
46. Lipponen P., Aaltoma S., Kosma V.M., Ala-Opas M., Eskelinen M. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol 1998 Oct, 186(2):157-164.
47. Bottger T.C., Youssef V., Dutkowski P., Maschek H., Brenner W., Junginger T. Expression of CD44 variant proteins in adenocarcinoma of Barrett's esophagus and its relation to prognosis. Cancer 1998 Sep 15, 83(6):1074-1080.
48. Fujita N., Yaegashi N., Ide Y., Sato S., Nakamura M., Ishiwata I., et al. Expression of CD44 in normal human versus tumor endometrial tissues: possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res 1994 Jul 15, 54(14):3922-3928.
49. Salles G., Zain M., Jiang W.M., Boussiotis V.A., Shipp M.A. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. Blood 1993 Dec 15, 82(12):3539-3547.